We investigated the role of hypoxaemia in cerebral blood flow (CBF), oxygen delivery (CDO 2 ) and neurovascular coupling (coupling of CBF to neural activity; NVC) in hypoxaemic chronic obstructive pulmonary disease (COPD) patients (n = 14). Resting CBF (duplex ultrasound), peripheral oxyhaemoglobin saturation (S pO 2 ; pulse-oximetry) and NVC (transcranial Doppler) were assessed before and after a 20 min wash-in of supplemental oxygen (∼3 l min −1 ). The peripheral oxyhaemoglobin saturation increased from 91.0 ± 3.3 to 97.4 ± 3.0% (P < 0.01), whereas CBF was unaltered (593.0 ± 162.8 versus 590.1 ± 138.5 ml min −1 ; P = 0.91) with supplemental O 2 . In contrast, both CDO 2 (98.1 ± 25.7 versus 108.7 ± 28.4 ml dl −1 ; P = 0.02) and NVC were improved.
INTRODUCTION
Patients with moderate to very severe chronic obstructive pulmonary disease (COPD) endure a state of chronic hypoxaemia as a consequence of suboptimal gas exchange. Literature on cerebral vascular regulation in COPD is sparse (Beaudin, Hartmann, Pun, & Poulin, 2017) , despite an elevated risk of cognitive impairment (Thakur et al., 2010) , dementia (Liao, Lin, Chang, Tu, & Kao, 2015) and ischaemic stroke (Feary, Rodrigues, Smith, Hubbard, & Gibson, 2010) ; this risk increases in proportion to disease severity (Portegies et al., 2016) . Physiological links between COPD, cerebrovascular dysfunction and risk of the aforementioned diseases have yet to be established.
In healthy individuals, a reduction in arterial oxygen content (C aO 2 ) leads to an increase in cerebral blood flow (CBF) attributable to cerebral vasodilator mechanisms (Hoiland, Bain, Rieger, Bailey, & Ainslie, 2016; Kety & Schmidt, 1948) , which may be continuously active in hypoxaemic COPD patients. Indeed, CBF is elevated in COPD commensurate to the level of hypoxaemia (Albayrak et al., 2006) ; however, whether this elevated CBF is of suffient magnitude to maintain cerebral oxygen delivery (CDO 2 ) is unknown. If patients
New Findings
• What is the central question of this study?
How does oxygen therapy influence cerebral blood flow, cerebral oxygen delivery and neurovascular function in chronic obstructive pulmonary disease patients?
• What is the main finding and its importance?
Oxygen therapy improves cerebral oxygen delivery and neurovascular function in chronic obstructive pulmonary disease patients. This improvement in cerebral oxygen delivery and neurovascular function might provide a physiological link between oxygen therapy and a reduced risk of cerebrovascular disease (e.g. stroke, mild cognitive impairment and dementia) in chronic obstructive pulmonary disease.
are hypoxaemic, low-flow oxygen (∼3l min −1 ) is typically prescribed (Medical Research Council Working Party, 1981; Nocturnal Oxygen Therapy Trial Group, 1980) with the goal of increasing the partial pressure of arterial oxygen (P aO 2 ) to > 60 mmHg while avoiding hyperoxia (Qaseem et al., 2011) . This therapy reduces mortality (Medical Research Council Working Party, 1981; Nocturnal Oxygen Therapy Trial Group, 1980) and the risk of cognitive impairment (Thakur et al., 2010) . Given the potential link between chronic cerebral hypoperfusion (i.e. vascular insufficiency; reduced CDO 2 ) and the pathogenesis of neurovascular injury and dementia (Iadecola, 2010) , understanding the influence of oxygen therapy on CBF, CDO 2 and neurovascular function in COPD is of immediate importance.
We examined two primary hypotheses: (i) that CBF would be reduced in COPD patients after O 2 normalization, leading to unchanged CDO 2 despite elevated C aO 2 ; and (ii) in the face of unchanged CDO 2 , no change in neurovascular function would be observed.
METHODS

Ethical approval
The study was approved by the institutional ethics committee (University of Split, Croatia; reg. no. 2181-198-03-03-13-0017) and the University of British Columbia Clinical Research Ethics Board (H16-01028). Written informed consent was obtained from all participants, and all experimental procedures conformed to the standards set by the Declaration of Helsinki, except for registration in a database.
Participants (COPD)
At the Split Clinical Hospital Centre Pulmonary Diseases Clinic (Split, Croatia), 342 COPD patients were screened for eligibility during hospital stays or ambulatory visits. Diagnosis of COPD was classified according to the criteria of the Global Initiative for Obstructive Lung Disease (GOLD; Vestbo et al., 2013) . The primary inclusion criterion was chronic hypoxaemia defined as arterial oxygen saturation of ≤93% objectively confirmed on at least two different occasions during the previous 6 months (n = 84). The related arterial blood gas values from these measurements are reported in Table 1 . Patients who had suffered from an acute exacerbation, active respiratory infection or infection of other localization within 6 weeks before the visit were excluded (n = 32). Likewise, patients who had a relevant coexisting condition, such as interstitial lung disease, cancer, renal failure, thromboembolic disease or major cardiovascular event during the previous year, were also excluded (n = 25). Those patients who could not provide informed consent or comply with the study protocol owing to a mental or physical condition were also excluded (n = 10).
One patient did not participate because of scheduling conflicts. Details on the remaining 16 patients included in the present study are presented in Table 1 .
Experimental overview (COPD)
Patients arrived at the laboratory having abstained from exercise, alcohol and caffeine for a minimum of 12 h. Additionally, the patients had fasted for 4 h, and current smokers had their last cigarette a minimum of 8 h before testing.
All cardiorespiratory variables were sampled continuously at 1 kHz via an analog-to-digital converter (Powerlab, 16/30; ADInstruments, Colorado Springs, CO, USA). Heart rate (HR) was measured by an ECG (lead II; ADI bioamp ML132), while beat-to-beat blood pressure was After ≥20 min of supine rest, resting volumetric CBF measurements were made using duplex ultrasound (Terason T3200; Teratech, Burlington, MA, USA) according to previously described methods (Thomas, Lewis, Hill, & Ainslie, 2015) . Measurements of the internal carotid artery (ICA) and vertebral artery (VA) were made ipsilateral to the MCA and PCA, respectively. Images were recorded and stored as video files for offline analysis using automated edgedetection software (Woodman et al., 2001) . No less than a 1 min video was used for the assessment of ICA and VA flow. Global CBF (gCBF) was estimated as twice the sum of the unilateral ICA and VA flow measurements. Reliable images of the ICA were collected in all patients; however, owing to excessive neck movement from respiration (e.g. sternocleidomastoid contraction), reliable VA images were captured in only seven patients; therefore, the resulting sample size for VA and gCBF is based on n = 7.
After the resting measurements, the neurovascular coupling ( After initial resting measurements and NVC, low-flow O 2 was administered via nasal cannula to normalize S pO 2 to ≥96% for 20 min, after which time resting measurements and NVC were repeated while O 2 supplementation was continued. Therefore, measurements of NVC and gCBF occurred 26.5 ± 3 and 30.0 ± 5.5 min after the onset of O 2 normalization, respectively. Two subjects withdrew for reasons unstated, rendering the final maximal sample size as n = 14 for pre-and post-O 2 normalization data.
Calculations
To provide further insight into the effect of oxygen therapy on cerebral vascular function, we have estimated CDO 2 by combining our pulseoximetry data and gCBF measures as follows:
where eCDO 2 represents estimated cerebral oxygen delivery and C aO 2 represents arterial oxygen content. Given the negligible contribution of dissolved O 2 to total C aO 2 (i.e. P aO 2 × 0.003) within physiological ranges of P aO 2 , we estimated C aO 2 from S pO 2 and haemoglobin concentration ([Hb]) as follows:
where eC aO 2 represents estimated arterial oxygen content. In the COPD patients, [Hb] was taken from two separate arterial blood gas samples during the 6 months before testing (i.e. same values as in Table 1 ).
Statistical analyses
Sample size was determined a priori based upon similar studies (Albayrak et al., 2006; Patterson, Heyman, & Duke, 1952) and sample size calculations (G*Power, v. 3.1, Universität Düsseldorf, Düsseldorf, Germany). It was determined that with a power of 0.8, 15 subjects would be required to detect a 100 ml min −1 change in gCBF (e.g. 13% change from typical value of 750 ml min −1 ) or a 25 ml min −1 change in unilateral ICA flow. Resting variables before and after O 2 normalization, and NVC parameters, were compared using Student's two-tailed paired t tests. When significant main effects were determined, Bonferroni post hoc tests were run, and corrected for multiple comparisons. Effect size was calculated as the mean difference divided by the standard deviation of the difference.
Statistical analyses were performed in the Statistical Package for the Social Sciences (v. 24, IBM Statistics, Armonk, NY, USA), with significance determined a priori as P < 0.05.
RESULTS
Oxygen normalization in COPD patients
In total, 14 participants completed both pre-and post-O 2 normalization testing. Resting variables are presented in Table 2 .
As expected, S pO 2 increased after O 2 normalization, from 91.0 ± 3.3 to 97.4 ± 3.0% (P < 0.01). There was no change in internal carotid artery flow, vertebral artery flow, gCBF (Figure 1 ), middle cerebral artery blood velocity, posterior cerebral artery blood velocity or MAP after O 2 normalization; however, there was a reduction in HR (P = 0.03). Maintained gCBF in combination with elevated S pO 2 resulted in improved eCDO 2 in the COPD patients (98.1 ± 25.7 versus 108.7 ± 28.4 ml dl −1 ; P = 0.02). The sample sizes for each comparison are noted in Table 2 .
Results from the neurovascular coupling trials (n = 11) before and after O 2 normalization are presented in Table 3 and Figure 2 .
Notably, the peak relative and absolute increases in PCA blood velocity (PCAv) were unaltered after O 2 normalization (Table 3 and Figure 2 ).
Despite this, the peak percentage increase in PCA cerebrovascular conductance (CVC) upon transition from eyes closed to eyes open increased by ∼40% (from 20.4 ± 9.9 to 28.0 ± 10.4%) after O 2 normalization (P = 0.04). Accordingly, the peak reduction in PCA cerebrovascular resistance (CVR) was also increased from −16.7 ± 7.3 to −21.4 ± 6.6% (P = 0.04) after O 2 normalization. We also observed TA B L E 2 Cerebral and cardiovascular variables before and after oxygen normalization in chronic obstructive pulmonary disease patients There is a paucity of experimental studies examining how altered resting arterial blood gases affect CBF in COPD patients (Beaudin et al., 2017) . Herein, we have provided support for the notion that O 2 normalization does not affect CBF in moderate to very severe COPD patients. We are aware that our gCBF measures are limited in sample size (n = 7), but we did collect ICA flow and intracranial velocity data in a larger percentage of our subjects (n = 14 for ICA flow), and these data reinforce our gCBF findings of no change gCBF (ml min with O 2 normalization. In comparison, the first study to investigate the influence of oxygen on CBF in COPD patients was in 1952, in which investigators administered 85-100% oxygen to hypoxaemic emphysema patients for 20 min increasing arterial O 2 saturation from 68 to 93% (Patterson et al., 1952) . One would expect removal of a hypoxic stimulus to reduce CBF secondary to disengaging hypoxic cerebral vasodilatation, but the opposite effect was observed;
DISCUSSION
CBF was elevated by ∼14% (Patterson et al., 1952 Our data in COPD patients are at odds with those previously collected in healthy individuals, whereby a reduction in gCBF is observed after O 2 normalization 1 week after arrival at an elevation of 5050 m (Willie et al., 2015) . Indeed, the prototypical response to withdrawal of a hypoxic stimulus is a reduction in CBF. This indicates that the lack of responsiveness to O 2 normalization in COPD is not representative of normal cerebrovascular function.
To interpret this notion judiciously, it is important to consider that differences between healthy individuals and COPD patients in response to O 2 normalization might be the result of differences in systemic inflammation, oxidative stress, age or medications and their potential influences on vascular control (Austin, Crack, Bozinovski, Miller, & Vlahos, 2016; Barnes, 2014; Hoffman, Albrecht, & Miletich, 1984 Lahousse, Tiemeier, Ikram, & Brusselle, 2015) . However, the physiological pathways linking COPD to deteriorated cerebral vascular function and increased risk have yet to be disentangled. Although cerebrovascular insufficiency is a contributory factor to coinciding cerebral vascular dysfunction and neurodegeneration (Iadecola, 2010) , O 2 therapy reduces the risk of cognitive impairment in COPD patients (Thakur et al., 2010) . Thus, it stands to reason that a mechanism for this is an improvement in CDO 2 . Indeed, the observed improvement in NVC coincided with improved CDO 2 and might represent a physiological link between long-term O 2 therapy and the reduced risk for dementia.
Given that CDO 2 is the product of C aO 2 and CBF, an increase in arterial 
Conclusions
Although low-flow supplemental O 2 does not alter volumetric gCBF in COPD patients, the increased S pO 2 results in improved CDO 2 and neurovascular function. This improvement in CDO 2 and neurovascular function with supplemental O 2 might underlie the cognitive benefits and reduced risk of cognitive impairment associated with O 2 therapy in COPD.
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